Management and Outcomes of Wilms Tumor With Suprarenal Intravascular Extension: A Pediatric Surgical Oncology Research Collaborative Study
- PMID: 37264925
- PMCID: PMC10829895
- DOI: 10.1097/SLA.0000000000005921
Management and Outcomes of Wilms Tumor With Suprarenal Intravascular Extension: A Pediatric Surgical Oncology Research Collaborative Study
Abstract
Objective: The purpose of this study was to describe management and outcomes from a contemporary cohort of children with Wilms tumor complicated by inferior vena caval thrombus.
Background: The largest series of these patients was published almost 2 decades ago. Since then, neoadjuvant chemotherapy has been commonly used to manage these patients, and outcomes have not been reported.
Methods: Retrospective review of 19 North American centers between 2009 and 2019. Patient and disease characteristics, management, and outcomes were investigated and analyzed.
Results: Of 124 patients, 81% had favorable histology (FH), and 52% were stage IV. IVC thrombus level was infrahepatic in 53 (43%), intrahepatic in 32 (26%), suprahepatic in 14 (11%), and cardiac in 24 (19%). Neoadjuvant chemotherapy using a 3-drug regimen was administered in 82% and postresection radiation in 90%. Thrombus level regression was 45% overall, with suprahepatic level showing the best response (62%). Cardiopulmonary bypass (CPB) was potentially avoided in 67%. The perioperative complication rate was significantly lower after neoadjuvant chemotherapy [(25%) vs upfront surgery (55%); P =0.005]. CPB was not associated with higher complications [CPB (50%) vs no CPB (27%); P =0.08]. Two-year event-free survival was 93% and overall survival was 96%, higher in FH cases (FH 98% vs unfavorable histology/anaplastic 82%; P =0.73). Neither incomplete resection nor viable thrombus cells affected event-free survival or overall survival.
Conclusions: Multimodal therapy resulted in excellent outcomes, even with advanced-stage disease and cardiac extension. Neoadjuvant chemotherapy decreased the need for CPB to facilitate resection. Complete thrombectomy may not always be necessary.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors report no conflicts of interest.
Figures





Similar articles
-
Management and outcome of pediatric Wilms tumor with malignant inferior Vena cava thrombus: largest cohort of single-center experience.Int J Clin Oncol. 2020 Jul;25(7):1425-1431. doi: 10.1007/s10147-020-01667-0. Epub 2020 Apr 5. Int J Clin Oncol. 2020. PMID: 32249334
-
Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus.Am J Surg. 2002 Mar;183(3):292-9. doi: 10.1016/s0002-9610(02)00782-1. Am J Surg. 2002. PMID: 11943130
-
Pediatric Abdominal Malignancies and Intravascular Extension: Contemporary Single-Center Experience.J Surg Res. 2022 Dec;280:396-403. doi: 10.1016/j.jss.2022.06.046. Epub 2022 Aug 26. J Surg Res. 2022. PMID: 36037617 Review.
-
Intravascular extension of Wilms tumor: Characteristics of tumor thrombus and their impact on outcomes.J Pediatr Urol. 2021 Feb;17(1):69.e1-69.e8. doi: 10.1016/j.jpurol.2020.10.003. Epub 2020 Oct 8. J Pediatr Urol. 2021. PMID: 33087302
-
Adult Wilms tumor with inferior vena cava thrombus and distal deep vein thrombosis - a case report and literature review.World J Surg Oncol. 2018 Feb 23;16(1):38. doi: 10.1186/s12957-018-1343-4. World J Surg Oncol. 2018. PMID: 29471818 Free PMC article. Review.
Cited by
-
Updated favourable-histology Wilms tumour risk stratification: rationale for future Children's Oncology Group clinical trials.Nat Rev Urol. 2025 Jun 20. doi: 10.1038/s41585-025-01055-1. Online ahead of print. Nat Rev Urol. 2025. PMID: 40542227 Review.
-
ASO Author Reflections: Surgical Management of Wilms Tumors with Intravenous Extension: A Multicenter Analysis of Clinical Management with Technical Insights.Ann Surg Oncol. 2024 Jul;31(7):4724-4725. doi: 10.1245/s10434-024-15325-6. Epub 2024 Apr 28. Ann Surg Oncol. 2024. PMID: 38679687 No abstract available.
-
Wilms Tumor with Vena Caval Intravascular Extension: A Surgical Perspective.Children (Basel). 2024 Jul 25;11(8):896. doi: 10.3390/children11080896. Children (Basel). 2024. PMID: 39201831 Free PMC article. Review.
-
Surgical Management of Wilms Tumors with Intravenous Extension: A Multicenter Analysis of Clinical Management with Technical Insights.Ann Surg Oncol. 2024 Jul;31(7):4713-4723. doi: 10.1245/s10434-024-15232-w. Epub 2024 Apr 5. Ann Surg Oncol. 2024. PMID: 38578552
-
Current surgical approaches to pediatric renal tumors.Pediatr Blood Cancer. 2025 Apr;72 Suppl 2(Suppl 2):e31118. doi: 10.1002/pbc.31118. Epub 2024 May 29. Pediatr Blood Cancer. 2025. PMID: 38809413 Review.
References
-
- Pastore G, Znaor A, Spreafico F, et al. . Malignant renal tumours incidence and survival in European children (1978-1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2103–2114. - PubMed
-
- Cunningham ME, Klug TD, Nuchtern JG, et al. . Global disparities in Wilms tumor. J Surg Res. 2020;247:34–51. - PubMed
-
- Dzhuma K, Powis M, Vujanic G, et al. . Surgical management, staging, and outcomes of Wilms tumours with intravascular extension: results of the IMPORT study. J Pediatr Surg. 2022;57:572–578. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous